Mainstay Medical starts commercialization of ReActiv8® for the treatment of Chronic Low Back Pain
1 February 2017
Dublin, Ireland: 1 February 2017 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, today announces the first sale and implant of ReActiv8 in Germany. The ReActiv8 implant was performed by Dr med Francis Kilian, Orthopedic and Neurosurgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz Germany. More info on Mainstay Medical's website.